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Abstract.  The spatial and temporal expression of the 
dystrophin gene has been examined during mouse em- 
bryogenesis, using in situ hybridization on tissue sec- 
tions with a probe from the 5' end of the dystrophin 
coding sequence. In striated muscle, dystrophin tran- 
scripts are detectable from about 9  d  in the heart and 
slightly later in skeletal muscle. However, there is an 
important difference between the two types of muscle: 
the heart is already functional as a contractile organ 
before the appearance of dystrophin transcripts, whereas 
this is not the case in skeletal muscle, where dystro- 
phin and myosin heavy chain transcripts are first de- 
tectable at the same time. In the heart, dystrophin 
transcripts accumulate initially in the outflow tract 
and, at later stages, in both the atria and ventricles. In 
skeletal muscle, the gene is expressed in all myocytes 
irrespective of fiber type. In smooth muscle dystrophin 
transcripts are first detectable from 11 d post coitum in 
blood vessels, and subsequently in lung bronchi and in 
the digestive tract. The other major tissue where the 
dystrophin gene is expressed is the brain,  where trans- 
cripts are clearly detectable in the cerebellum from 
13 d.  High-level expression of the gene is also seen in 
particular regions of the forebrain involved in the 
regulation of circadian rhythms, the endocrine system, 
and olfactory function, not previously identified in this 
context. The findings are discussed in the context of 
the pathology of Duchenne muscular dystrophy. 
D 
LETIONS and other mutations in the human X-linked 
dystrophin gene are responsible for the myopathies 
of Duchenne and Becker (reviewed in Chamberlain 
and Caskey, 1990).  It is therefore of medical importance as 
well as of biological interest to understand the function of 
dystrophin and when and where the gene is expressed. The 
full-length dystrophin messenger RNA is 14 kb long and is 
encoded by at least 75 exons distributed over 2.5 megabases 
of the human X  chromosome (reviewed in  Hoffman and 
Kunkel, 1989).  Two transcripts of this size have been iden- 
tiffed that are transcribed from two distinct 5' promoters, one 
of which is active in muscle and in glia, and the other in neu- 
rons (Barnea et al.,  1990).  At least one other internal pro- 
moter is present encoding a 6.5-kb mRNA corresponding to 
the 3' half of the coding sequence, and found in a number 
of nonmuscle tissues, including liver and brain (Bar et al., 
1990).  Further dystrophin transcripts are generated from 
the mouse and human genes by alternative splicing of 3' 
exons (Feener et al., 1989; Bies et al., 1992). Some of these 
carboxy-terminal isoforrns are expressed in different tissues 
and at different stages of development (Bies et al., 1992). In 
addition to the X-linked dystrophin gene, an autosomal gene 
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encoding a  dystrophin-related protein has been identified 
(Love et al,,  1989). 
The full-length 427-kD  protein encoded by the X-linked 
dystrophin gene is present in skeletal muscle, localized to the 
sarcolemma (Ervasti et al., 1990),  where it exists as a large 
oligomeric complex in association with a number of glyco- 
proteins (Yoshida and Ozawa, 1990; Ervasti and Campbell, 
1991). The spectrin-like structure of the molecule and its lo- 
calization  suggest  that  dystrophin  may  be  important  in 
stabilizing the plasma membrane, acting as an anchor for 
cytoskeletal or sarcomeric structures. Antibody studies have 
suggested some concentration of  the protein at myotendinous 
and neuromuscular junctions (e.g.,  Shimizu et al.,  1989; 
Jasmin et al.,  1990;  Fardeau et al.,  1990;  Sealock et al., 
1991; Yeadon et al., 1991) in addition to the presence of the 
dystrophin-related protein (Ohlendieck et al.,  1991) at this 
site.  Dystrophin protein is also present in cardiac and in 
smooth muscle, although in the latter the plasma membrane 
is  considerably  less  dystrophin  immunoreactive  (e.g., 
Hoffman et al.,  1988;  Byers et al.,  1991). The dystrophin 
gene is also expressed in brain at a level ~10% that in muscle 
(Chamberlain et al., 1988). The protein is present in a num- 
ber of regions in the brain (Jung et al.,  1991). It is more 
abundant in neurons of the cerebral and cerebellar cortices 
than in other parts of the brain, and has been localized at the 
postsynaptic membrane, in the mouse (Lidov et al.,  1990). 
Localization of dystrophin mRNA has also been reported for 
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kinje cells of the cerebellum (Gorecki et al., 1991). In addi- 
tion to muscle and brain, low levels of transcripts from the 
X-linked dystrophin gene have been detected by polymerase 
chain reaction (PCR) ~ analysis in other nonmuscle tissues 
(Chelly  et  al.,  1988).  The  dystrophin-related autosomal 
gene is expressed at the neuromuscular junction, and at a 
higher level in smooth muscle and in some nonmuscle tissues 
such as the kidney (Love et al.,  1991). 
A few studies have been carried out on dystrophin gene ex- 
pression in immature tissues. Dystrophin transcripts were 
detected by PCR analysis in RNA from skeletal muscle and 
brain in the mouse from embryonic day 14 (Chamberlain et 
al., 1991). In humans from 8 wk of fetal development in limb 
muscle, dystrophin protein is first observed at the myoten- 
dinous junction and is subsequently integrated into the sar- 
colemma (Wessels et al., 1991). Dystrophin is first detected 
in  the  sarcoplasm  of human  myotubes in  tissue  culture 
(Miranda et al., 1988). A recent study on human limbs using 
antibodies also reported dystrophin immunostaining from 9 
wk gestation, with the presence of two distinct protein bands 
that vary in relative abundance as development proceeds 
(Clerk et al., 1992). This is in keeping with an earlier report 
on mouse muscle (Dickson et al., 1988).  In rats, by immu- 
nohistochemicai and immunoblot analysis dystrophin pro- 
tein is detected from embryonic day 19 in the plasma mem- 
brane of the extensor digitorum longus limb muscle, and 
from embryonic day 15 as a weak diffuse cytoplasmic label- 
ing (Hagiwara et al.,  1989).  In the rat heart,  dystrophin 
protein was not detected until just before birth, whereas dys- 
trophin mRNA was detectable by PCR analysis from em- 
bryonic day 10 (Tanaka et al., 1991). In the rat brain, dystro- 
phin protein has been detected from 18 d of gestation (Jung 
et al.,  1991); earlier stages were not examined. 
We have carried out a  systematic analysis of dystrophin 
gene expression during mouse embryonic and fetal develop- 
ment, using in situ hybridization on tissue sections, with a 
probe that recognizes transcripts from the 5' region of the 
gene, i.e., the 14-kb transcripts expressed in brain and mus- 
cle. This approach permits us to define when and where dys- 
trophin transcripts first appear during mammalian develop- 
ment. We note that during the formation of skeletal muscle, 
transcripts accumulate with those of  myosin, but in the heart, 
myosin mRNAs and the initiation of contraction precede the 
first detectable dystrophin mRNAs by at least 24 h. Dystro- 
phin transcripts accumulate in smooth muscle and in the 
brain in the cerebellum and hippocampus, and also in previ- 
ously unidentified locations in the forebrain, among which 
are the tissues that will give rise to parts of the pineal and 
pituitary glands. These observations are discussed in an em- 
bryological context and in terms of the function of the gene 
product and its dysfunction in disease. 
Materials and Methods 
Preparation and Prehybridization of Tissue Sections 
The protocol that was used to fix and embed mouse embryos is described 
in detail in Lyons et al. (1990a). Briefly, embryos were fixed in 4% parafor- 
1. Abbreviations used in this paper:  MHC, myosin heavy chain; MHCa, 
mouse atrial myosin heavy chain; MLC1V, mouse ventricular myosin light 
chain 1; PCR, polymerase chain reaction. 
maldehyde in PBS, dehydrated,  and infiltrated with paraffin.  5-7-~tm-thick 
serial sections were mounted on subbed slides. One to three sections were 
mounted on each slide, deparnfiinized  in xylane,  and rehydrated.  The sec- 
tions were digested with proteinase K, postfixed,  treated with triethanola- 
mine/acetic  anhydride,  washed,  and dehydrated. 
Probe Preparation 
The cRNA transcripts were synthesized  according to the manufacturer's 
(Stratagene,  La Jolla, CA) conditions and labeled with 35S-UTP (>1,000 
Ci/mmol; Amersharn Corp., Arlington Heights,  IL). eDNA probes were 
subcloned into Bluescribe  + and pSP64/65 plasmids to generate both sense 
and antisense probes.  The following probes were used: The common probe 
used was a 530-bp BglII/HindlII fragment spanning exons 16-20 of the dys- 
trophin gene.  These exons  are transcribed in all  14-kb gene transcripts 
(Chamberlain et al.,  1988).  A number of other myogenic regulatory and 
muscle structural protein mRNA probes, which have been described previ- 
ously (Sassoon et al.,  1988; Sassoon et al.,  1989; Lyons et al.,  1990a,b; 
Lyons et al., 1991a,b,c; Ott et al., 1991; Bober et al., 1991), have also been 
used to compare the patterns of expression of other muscle genes with that 
of dystrophin.  Results with the following probes are presented: 3' untrans- 
lated region of the mouse ventricular  myosin light chain 1 (MLC1V) mRNA 
(Lyons  et al.,  1990a);  3' end of the mouse atrial myosin  heavy chain 
(MHCc0  mRNA  (Lyons et al.,  1990b);  3' end of the mouse myogenin 
mRNA (Sassoon  et al.,  1989). 
Hybridization and Washing Procedures 
The hybridization and posthybridization procedures are as described by 
Lyons et al. (1990a). Sections were hybridized overnight  at 45-52 *C in 50 % 
deionized formamide, 0.3 M NaCI, 20 mM Tris-HC1, pH 7.4, 5 mM EDTA, 
10 mM NaPO4,  10% dextran sulfate,  1￿  Denhardt's, 50 t~g/ml yeast RNA, 
and 35-75,000  cpm/#l 35S-labeled cRNA probe.  The tissue was subjected 
to stringent washing at 65~  in 50% formamide,  2￿  SSC,  10 mM DTT, 
and washed in PBS before treatment with 20/~g/ml RNAse A at 37~  for 
30 min. After washes in 2￿  SSC and 0.1￿  SSC for 10 min at 370C, the 
slides were dehydrated and dipped in Kodak NTB-2 nuclear track emulsion 
and exposed  for 1 wk in light-tight boxes with desiccant at 4~  Photo- 
graphic development was carried out in Kodak D-19. Slides were analyzed 
using both light- and dark-field  optics of an Axiophot microscope (Carl 
Zeiss, Inc., Thornwood,  NY). 
Dystrophin gene expression was examined on paraffin sections ofpostim- 
plantation mouse embryos by in situ hybridization,  using a probe from the 
5' end of the mouse dystrophin gene covering exons  16-20, which cor- 
respond to the fl spectrin-like region of the gene. This probe therefore de- 
tects all  14-kb  gene transcripts from both 5' neuronal and muscle-type 
promoters (Barnea et al., 1990), but not transcripts generated from internal 
promoters such as encoding the 6.5-kb transcript expressed in liver (Bar et 
al.,  1990). 
Results 
Skeletal Muscle 
All body musculature in higher vertebrates is derived from 
the somites, which form in a rostro-caudal gradient as a re- 
sult  of  segmentation  of the  paraxial  mesoderm  (Rugh, 
1990).  The first skeletal muscles to form are the myotomes 
in the central portion of the somite. Dystrophin transcripts 
are first detected in the myotomes of 9.5-d embryos (27 so- 
mites; Fig. 1, A and B). This is 1 d later than transcripts such 
as those of a-cardiac actin (Sassoon et al., 1988) or the myo- 
genic regulatory sequence, myogenin (Sassoon et al., 1989), 
which are present in the newly formed myotome from 8.5 d. 
The first sarcomeric myosin heavy chain transcripts, on the 
other hand, also begin to accumulate at this time (Lyons et 
al.,  1990a).  Comparison of the distribution of dystrophin 
transcripts with those of myogenin in an adjacent section of 
the same somite (Fig. 1, C and D) indicates that whereas the 
latter are expressed throughout the myotome, the former are 
limited to the ventral region where cells with an elongated 
The Journal of Cell Biology, Volume 119, 1992  812 Figure 1. Dystrophin transcripts in the myotome. Adjacent transverse sections of a 27-somite (~9.5 d) mouse embryo showing a somite 
at the level of the forelimb. Phase contrast (A) and dark field (B) photomicrographs hybridized with the dystrophin probe; phase contrast 
(C) and dark field (D) photomicrographs hybridized with the myogenin  probe, d, dermatome; m, myotome; s, sclerotome; l, limb-bud. 
Bar, 45 #m. 
morphology, probably at a more advanced stage of  differenti- 
ation  (Sassoon  et al.,  1988),  are present.  The  myogenln 
labeling of this region is less intense (Fig. 1 D), but this may 
be  due  to  the  plane  of section.  The  level  of dystrophin 
mRNAs in skeletal muscle gradually increases with develop- 
ment. The distribution of grains when examined at higher 
magnification is not uniform with the dystrophin probe (Fig. 
2, C and D), in contrast to other muscle sequences that show 
more  uniform  distribution  along  the  fibers  (results  not 
shown; Lyons et al.,  1990a and 1991c). This is evident at 
14.5-15.5  d (Fig. 2, B-D) and at later stages. By 17.5 d, the 
intensity of the signal with the dystrophin probe has reached 
its maximum level. Transcripts are detected in all muscles 
of the hind limb, including the soleus, a slow muscle, and 
in fast muscles such as the extensor digitorum longus (Fig. 
2, E and F). Dystrophin is expressed not only in developing 
skeletal muscle, but also in cardiac and smooth muscle (Fig. 
2, A and B). 
Cardiac Muscle 
The heart is formed from lateral mesoderm. It is initially 
present as a cardiac tube from ~7 d in the mouse embryo. 
By ~8 d it has begun to contract, and by 9.5 d atrial and ven- 
tricular compartments can be clearly distinguished. Dystro- 
phin transcripts are first detectable by in situ hybridization 
in an 18-somite embryo (",,9 d), and are still only  just visible 
above background in a 21-24-somite embryo (Fig. 3, A and 
B). At a slightly later stage in a 10-d-old embryo, transcripts 
have begun to accumulate (Fig. 3,  C and D). Thus, in the 
heart a functional sarcomere is present well before dystro- 
phin gene expression, in contrast to the situation in the myo- 
tome where dystrophin transcripts begin to accumulate at 
about the same time as those for MHC. At later stages dys- 
trophin continues to be expressed in both atrial and ventricu- 
lar compartments of the heart at a time when myosin iso- 
forms are beginning to be restricted. Thus, at 11.5 d MHCot 
transcripts are already beginning to accumulate preferen- 
tially in the atria (Fig. 4  C), and MLC1V in the ventricle 
(Fig. 4 D) (Lyons et al.,  1990b),  whereas dystrophin shows 
a similar distribution in both compartments (Fig. 4 B). The 
intensity of labeling  with  the  dystrophin probe  is  much 
lower, and this despite the fact that the probe is considerably 
longer than the myosin probes, indicating the relatively low 
level  of expression of this gene.  Subsequently, dystrophin 
transcripts continue to accumulate in the heart reaching a 
maximum level between 14.5 and 15.5 d (see Fig. 2, A and 
B), and then progressively declining to give a lower, but still 
detectable, signal at 16 d and postnatally (results not shown). 
Smooth Muscle 
Smooth muscle is mainly present in the embryo in the walls 
of blood vessels, and of the digestive and respiratory sys- 
Houzelstein et al. Dystrophin Transcripts in Mouse Embryos  813 Figure 2. Expression of dystmphin is developing  skeletal muscle. Phase contrast (A) and dark field (B) photomicrographs of a parasagittal 
section of a 14.5-d mouse embryo hybridized with the dystrophin probe showing labeling of intercostal (im) and diaphragm (di) skeletal 
muscles, of  cardiac muscle (h) and of smooth muscle in the lung (iu). Bar, 360/zm. Phase contrast (C) and dark field (D) photomicrographs 
of a parasagittal section showing  trunk musculature of a 15.5-d embryo. Bar, 45/~m. Dark field photomicrographs showing  adjacent serial 
transverse sections of a 17.5-d embryo hindlimb hybridized with the dystrophin probe (E) and the myogenin  probe (F). f, fibula; t, tibia; 
s, soleus; edl, extensor digitorum longus. Bar, 180/zm. 
tems. Both the digestive and respiratory tubes are formed 
from embryonic endoderm. Smooth muscle surrounding the 
endodermal layer is derived from adjacent mesenchyme. 
By 10 d of embryonic development the lung buds form, in 
the region of the pharynx,  as extensions of the laryngo- 
tracheal groove, which itself is a prolongation of the foregut. 
At this stage the trachea separates from the esophagus. By 
11 d the bronchi are formed and shortly afterwards begin to 
develop branches. At 12 d dystrophin transcripts become de- 
tectable in the walls of the bronchi and bronchioli (Fig. 5, 
A and B),  and the gene continues to be expressed in the 
smooth muscle of the lung at later stages (Fig. 2, A and B, 
and results not shown). 
Beginning at 11 d post coitum, the primitive gut forms the 
esophagus,  stomach,  small  intestine,  and  large  intestine 
(Rugh,  1990;  Theiler,  1989).  Posterior to the pharynx the 
digestive tube constricts from 11 d to form the esophagus, 
stomach,  small intestine,  and large  intestine.  Dystrophin 
The Journal of Cell Biology, Volume  119, 1992  814 Figure 3. Dystrophin expression in the heart. Phase contrast (A) and dark field (B) photomicrographs of a 21-24-somite embryo (~9.5 d) 
hybridized with the dystrophin probe. Bar, 180/zm. Phase contrast (C) and dark field (D) photomicrographs ofa 27-somite  embryo hybrid- 
ized with the same probe, a, atria; v, ventricle. Bar, 90/~m. 
transcripts are only detected relatively late, at 14.5 d in the 
walls of the esophagus and very weakly in the smooth mus- 
cle of the stomach and intestine. It is only at 15.5 d that the 
latter labels more strongly with the dystrophin probe (Fig. 
5, E  and F). 
Angiogenesis in the mouse begins at "~8 d with the appear- 
ance of the dorsal and ventral aortae; by 9 d the circulation 
is established. Most of the major blood vessels appear by 
11 d. Initial detection of dystrophin transcripts in the smooth 
muscle of blood vessels is difficult; the signal is weak, at 
least in part because of the thinness of the layer of muscle 
tissue. We first detect a signal in blood vessels of the embryo 
at 11.5 d in the walls of the dorsal aorta, and in the extraem- 
bryonic circulatory system from 12.5 d (results not shown). 
As the embryo develops an increasing number of blood ves- 
sels are labeled with the dystrophin probe. At 15.5 d, for ex- 
ample,  a  clear  signal  is  detected,  which is  only slightly 
weaker than that in adjacent skeletal muscle (Fig. 5, C and 
D). Unlike the latter, the signal in smooth muscle is uniform 
rather than punctate. 
Dystrophin Expression in the Nervous System 
The essential features of  the brain begin to be established rel- 
atively early during embryogenesis (from •8  d) and can be 
identified in large part from 11  d. By 14 d the embryonic 
brain is typicall:- that of  a mammal (Rugh, 1990). From 13 d 
dystrophin transcripts are detectable in the hindbrain in the 
metencephalon or cerebellum (Fig. 6, A and B), which con- 
tinues to give a low signal during subsequent development. 
The pons, adjacent to the cerebellum, also gives a very low 
signal. At this stage dystrophin transcripts are also present 
in the forebrain, localized to the roof of the diencephalon, 
in the epithalamus (Fig.  6,  C and D),  and by  14 d  in the 
epiphysis or the pineal body (Fig. 6, E and F), which will 
form the pineal gland. Another structure that is partially de- 
rived  from the  diencephalon is  the pituitary gland.  This 
forms from brain neurectoderm and from oral plate ecto- 
derm. Part of the base of the diencephalon detaches by 12 d 
to form the infundibular process, which is the neural part of 
the pituitary. The glandular part of the pituitary develops 
from Rathke's pocket, derived from the oral plate. It begins 
to function as a secretory organ between 17 and 18 d of de- 
velopment. By 14.5 d the dystrophin probe gives a relatively 
strong signal over Rathke's pocket (Fig. 7, C and D). Dystro- 
phin transcripts are also detectable from 13.5 d at a very low 
level  in a limited area over the central region of the dien- 
cephalon,  the  thalamus  (results  not  shown),  and  in  the 
hypothalamus at the base of the diencephalon (Fig. 7, A and 
B). In Fig. 7 B, a strong signal is also seen in tissue underly- 
ing the olfactory epitheliunl on either side of the palate. 
Dystrophin transcripts are also detectable in parts of the 
peripheral nervous system. A very weak signal is seen over 
Houzelstein et al. Dystrophin Transcripts in Mouse Embryos  815 Figure 4.  Comparison of dystrophin and myosin transcripts in the heart. Phase contrast (A) and dark field (B-D) photomicrographs of 
adjacent parasagittal sections of an 11.5-d embryo hybridized with the dystrophin probe (A and B), a probe specific for MHCa transcripts 
(C), and for MLC1V transcripts (D).  a, atria; v, ventricle; j, arterioventricular junction. Bar, 180 #rn. 
the spinal ganglia from 13 d (results not shown). This is also 
the case for a population of cells in the spinal cord from 
14.5 d (results not shown). The presence of dystrophin in the 
spinal cord of 18-wk human fetuses has already been noted 
(Hoffman et al.,  1988). 
Discussion 
The most evident lesion in patients with Duchenne or Becker 
muscular dystrophies is in skeletal muscle. We show here 
that transcription of the dystrophin gene is detectable when 
skeletal myogenesis is initiated in the embryo. This process 
is asynchronous, with ot-actin, for example, preceding myo- 
sin heavy chain by at least 1 d (Lyons et al.,  1990a)  in the 
first skeletal muscle, the myotome. Dystrophin is not among 
the earliest muscle markers, but the transcripts begin to ac- 
cumulate at the same time as those of the embryonic MHC. 
We would suggest that the activation of the dystrophin gene 
at this early stage of myogenesis reflects the importance of 
the protein in functional skeletal muscle. The question of 
when the protein first accumulates is open at present. In the 
rat (Hagiwara et al.,  1989),  low levels of protein were de- 
tected in limb skeletal muscle at embryonic day 15, which 
was the earliest time point examined. In this species primary 
fibers are present at this stage, and the protein is not yet con- 
centrated at the plasma membrane, as it is later. 
In the mouse, dystrophin transcripts are accumulated in 
all muscle masses, throughout development. There is no ap- 
parent distinction between fiber types. The distribution of 
the transcripts within muscle fibers, however,  ceases to be 
uniform from about the time when innervation takes place 
(Ontell and Kozeka,  1984).  A higher concentration of the 
X-linked dystrophin protein has been reported at the neu- 
romuscular junction (Byers et al., 1991), and the possibility 
that dystrophin transcripts are being transcribed at a higher 
level of subsynaptic nuclei requires further investigation. 
As in the case of other muscle genes, the dystrophin gene 
is  transcribed  throughout  skeletal  muscle  formation and 
maturation. Different myogenic factors of the MyoD family, 
involved in the transcriptional activation of many muscle 
genes,  are present at different developmental stages.  Ini- 
tially, when the dystrophin gene is activated in the myotome, 
myf-5 and myf-6 are probably present, whereas in the limb, 
MyoD and myogenin are the main myogenic regulatory pro- 
teins, to be replaced later by myf-6 (see Buckingham, 1992). 
If this family plays a role in regulating dystrophin transcrip- 
tion in skeletal muscle, there is no absolute requirement for 
a single factor. Recent results show that a CCArGG box pres- 
ent in the proximal promoter is important for preferential ex- 
pression of the gene in muscle, thus pointing to the probable 
role of proteins other than those of the MyoD family (Gil- 
genkrantz et al.,  1992). 
The Journal of Cell Biology, Volume  119, 1992  816 Figure 5.  Dystrophin expression in smooth muscle. Phase contrast (A) and dark field (B) photomicrographs of a section through the lung 
of a 12.5-d embryo hybridized with the dystrophin probe showing signal in the lung. Bar, 180 #m. Phase contrast (C) and dark field (D) 
photomicrographs of a parasagittal section of a 15.5-d embryo, hybridized with the dystrophin probe, showing signal in a blood vessel 
(bv), compared with skeletal muscle (m). Bar, 90 #m. Phase contrast (E) and dark field (F) photomicrographs of a parasagittal section 
of a 15.5-d mouse embryo, hybridized with the dystrophin probe, showing signal in the digestive tract. Bar, 180 #m. br, bronchiole; bv, 
blood vessel; m, skeletal muscle; li, liver; st,  stomach; i, intestine. Arrowheads in E and F indicate the smooth muscle layer hybridized 
with the dystrophin probe (F). In B, arrowheads indicate signal in the bronchiolar wall. 
In  the  heart,  distinct  from  skeletal  muscle,  dystrophin 
transcripts are not detectable initially when myosin is pres- 
ent and the heart is already contracting. It is noteworthy that 
malfunction of the myocardium is less progressive and de- 
bilitating in Duchenne patients than malfunction of skeletal 
muscle  (see  Moser,  1984).  Dystrophin is  expressed uni- 
formly in both ventricular and atrial compartments. The fact 
that  at  certain  specialized locations,  such  as  the  outflow 
tract, transcripts are more abundant may reflect the greater 
contractile strain placed on the sarcolemma at these sites. 
Myosin gene expression in this region also has distinct fea- 
tures (Lyons et al.,  1990b). The conducting system that is 
associated with this part of the heart has been noted to be 
particularly affected in Duchenne patients (Moser, 1984). It 
Houzelstein et al. Dystrophin Transcripts in Mouse Embryos  817 Figure  6.  Expression of dystrophin in the central nervous system. Phase contrast  (A) and dark field (B) photomicrographs  of a frontal 
section of a 13-d mouse embryo showing a region of the hindbrain,  hybridized with the dystrophin probe. Bar,  180 #m. Phase contrast 
(C) and dark field (D) photomicrographs  of a frontal section of a 13-d mouse embryo showing a region of the forebraln hybridized with 
the dystrophin probe. Bar, 90 #m. Phase contrast (E) and dark field (F) photomicrographs of a parasagittal section of a 14-d mouse embryo 
showing a region of the forebraln hybridized with the dystrophin probe. Bar,  180 #m. aq, aqueduct of Sylvius; v', fourth ventricle;  cb, 
cerebellum;  v, third ventricle;  ep, epithalamus; p, pineal body; pir, pineal recess. 
was noted by Bies et al. (1992) that human cardiac Purkinje 
fibers  express  dystrophin-spliced  forms  more  similar  to 
those in brain than in muscle. In rat hearts (Tanaka et ai., 
1991),  dystrophin mRNA was detected from embryonic day 
10,  which correlates with our observations on the mouse, 
given that the latter species develops more rapidly and that 
the in situ hybridization technique is less sensitive than PCR. 
However, the protein was not detectable until embryonic day 
19. This may reflect the fact that the mAb used was against 
a COOH peptide, and this is a region where differential splic- 
ing has been shown to occur (Feener et al.,  1989).  The 5' 
probe used  in  our  experirnents  would  not  distinguish  be- 
tween different sequences resulting from alternative splicing, 
which has been shown by PCR analysis to occur in develop- 
ing murine striated muscle and brain (Bies et al., 1992). Al- 
ternatively, translational control of dystrophin gene expres- 
The Journal of Cell Biology, Volume 119, 1992  818 Figure  7. Expression of dystrophin in the olfactory apparatus, and in Rathke's  pocket. Phase contrast (A) and dark field (B) photomicro- 
graphs of a frontal section of a 13.5-d mouse embryo in the head region hybridized with the dystrophin probe. Bar, 180/zm. Phase contrast 
(C) and dark field (D) photomicrographs ofa parasagittal section of a 14.5-d mouse embryo in the head region hybridized with the dystro- 
phin probe. Bar, 180 #m. p, palate; oe, olfactory epithelium; hy, hypothalamus; sc, sphenoid cartilage; rp, Rathke's pocket. 
sion may be important. In skeletal muscle, for example, this 
is clearly the case for the myogenic regulatory factor, myo- 
genin (Cusella de Angelis et al.,  1992). 
In smooth muscle the question of probe specificity is par- 
ticularly  critical,  since  the  dystrophin-related  autosomal 
gene is expressed at a particularly high level in this tissue 
(Love et al., 1991), where we detect a clear signal. Sequence 
is not available for the equivalent 5' region of the dystrophin- 
related gene; however,  in situ hybridization conditions are 
relatively stringent, and the fact that we see no signal in the 
kidney where the dystrophin related protein is expressed at 
a high level (Love et al., 1991) strongly suggests that cross- 
hybridization with this sequence is not a problem. The pres- 
ence of dystrophin protein has been reported in smooth mus- 
cle (Hoffman et al., 1988; Byers et al., 1991). We show here 
that the gene is activated as smooth muscle forms in the fore 
gut and its prolongations, in the lung, for example. In the hind 
gut, transcripts are detectable relatively later in the stomach 
and intestine. Perturbations in smooth muscle function are 
not a major feature of the pathology of Duchenne dystrophy. 
A  contributory factor to respiratory failure, which is fre- 
quently a cause of death in Duchenne patients, may be the 
lack of dystrophin in the walls of the bronchi and bronchioli. 
About one-third of patients with Duchenne muscular dys- 
trophy suffer from some degree of mental impairment (see 
Moser,  1984).  Transcription of the dystrophin gene to give 
a 14-kb transcript in the brain (Chamberlain et al., 1988) is 
probably initiated from both upstream promoters (Barnea et 
al.,  1990; Bies et al.,  1992).  Use of the internal promoter, 
which generates a  6.5-kb  mRNA (Bar et al.,  1990),  and 
different splicing mechanisms also contribute to the com- 
plexity of dystrophin gene transcripts present in this tissue 
(Bies et al., 1992). It is not yet known whether different iso- 
forms are confined to specific structures in the brain, how- 
ever, in the adult, accumulation of dystrophin protein (Lidov 
et al.,  1990; Jung et al.,  1.991) and transcripts (Gorecki et 
al.,  1991) in the Purkinje cells of the cerebellum has been 
demonstrated. The cerebellum is involved in the coordina- 
tion of movements; older mdx mice have been reported to 
have some lack of coordination and tremors (Bulfield et al., 
1984).  In keeping with these results we detect dystrophin 
transcripts in the cerebellum shortly after its formation dur- 
ing embryogenesis. On the other hand, in the cerebellar cor- 
tex, where both protein and transcripts were detected in the 
adult (see Lidov et al.,  1990;  Jung et al.,  1991; Gorecki et 
al., 1991), we did not detect a clear signal above background 
in the immature tissue. This may be partly due to the pres- 
ence of other isoforms not recognized by our probe; however 
Gorecki et al. (1991) detected a signal in the cortex, and in 
the hippocampus using oligonucleotides derived from the 5' 
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also negative  in the prenatal  brain in our experiments.  A 
clear signal is present however in another region of the fore- 
brain, in structures forming part of the diencephalon.  Label 
is seen in the epithalamus.  The habenula structures of this 
region are important in assuring the contact between the ol- 
factory centers and the brain. The epiphysis, which will form 
the pineal gland, also expresses the dystrophin gene at a high 
level. The pineal gland plays a role in the establishment of 
circadian rhythms, via perception of dark/light cycles.  Cells 
of the gland remain multipotent and can, for example, form 
skeletal  muscle when cultured  in vitro OVatanabe et al., 
1988). 
Another striking site of dystrophin gene expression in the 
embryo is in the precursor cells that will form the glandular 
component of the pituitary. In this case, dystrophin may be 
playing  a role in conjunction with the cytoskeleton in the 
secretory  processes essential  for function of the gland.  It is 
perhaps  significant  that a clear  signal  is also seen in the 
hypothalamus,  which is a region  of the diencephalon that 
affects pituitary function.  Given the high level of dystrophin 
transcription in Rathke's pocket, it is probable that pituitary 
function is perturbed when the gene is not expressed cor- 
rectly, during formation of the gland. 
In the light of the new localization  of dystrophin gene ex- 
pression described here,  we would predict  that Duchenne 
patients may suffer from endocrine malfunction, from per- 
turbations in circadian and seasonal rhythms, and from ol- 
factory  deficiencies. 
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